Metabolic & body composition
Dual Regulator (GLP-1/GIP) — tirzepatide
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
Tirzepatide, listed as Dual Regulator (GLP-1/GIP) because compounded formulations cannot be marketed under the drug's commercial name. A GIP/GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
What it is
This is tirzepatide, a dual GIP/GLP-1 receptor agonist. The dual mechanism produces a larger metabolic effect than GLP-1 alone in head-to-head trials, and it has also been studied in sleep apnea and heart-failure populations. The active ingredient is the same one found in FDA-approved products, but compounded formulations are not themselves FDA-approved and are dispensed only by licensed, FDA-registered compounding pharmacies after a physician evaluation.
What it's studied for
- Weight reduction above 20% at higher doses in the SURMOUNT trials
- Superior HbA1c reduction versus the single regulator in SURPASS-2
- Obstructive sleep apnea severity
How it's used in practice
- Dose-escalated over months rather than weeks
- Same muscle-preservation requirements as any GLP-1 protocol
- Body composition, not scale weight, is the metric that matters
What you should know before asking about it
- Prescription only, after physician evaluation
- Same thyroid C-cell and pancreatitis warnings as the GLP-1 class
- Gastrointestinal effects are dose-dependent and manageable with slower titration
Frequently asked questions.
- What is Dual Regulator (GLP-1/GIP) — tirzepatide?
- This is tirzepatide, a dual GIP/GLP-1 receptor agonist. The dual mechanism produces a larger metabolic effect than GLP-1 alone in head-to-head trials, and it has also been studied in sleep apnea and heart-failure populations. The active ingredient is the same one found in FDA-approved products, but compounded formulations are not themselves FDA-approved and are dispensed only by licensed, FDA-registered compounding pharmacies after a physician evaluation.
- What is Dual Regulator (GLP-1/GIP) — tirzepatide studied for?
- Published and ongoing research looks at weight reduction above 20% at higher doses in the SURMOUNT trials; superior HbA1c reduction versus the single regulator in SURPASS-2; obstructive sleep apnea severity. These are areas of study, not promised outcomes.
- Is Dual Regulator (GLP-1/GIP) — tirzepatide FDA-approved?
- Dual Regulator (GLP-1/GIP) — tirzepatide is not FDA-approved as a finished product. It is prepared by licensed, FDA-registered compounding pharmacies and can be dispensed only on a prescription written after a physician evaluation.
- How is Dual Regulator (GLP-1/GIP) — tirzepatide typically used?
- Dose-escalated over months rather than weeks Same muscle-preservation requirements as any GLP-1 protocol Body composition, not scale weight, is the metric that matters Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with Dual Regulator (GLP-1/GIP) — tirzepatide?
- Prescription only, after physician evaluation Same thyroid C-cell and pancreatitis warnings as the GLP-1 class Gastrointestinal effects are dose-dependent and manageable with slower titration
Sources
- 1.Published literature on Dual Regulator (GLP-1/GIP) — tirzepatide— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Metabolic & body composition
Single Regulator (GLP-1) — semaglutide
Semaglutide, listed as Single Regulator (GLP-1) because compounded formulations cannot be marketed under the drug's commercial name. A GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.
Triple Regulator (GLP-1/GIP/glucagon)
An investigational triple agonist (GLP-1, GIP and glucagon) in late-stage clinical trials — not approved, not prescribable.
AOD-9604
A fragment of human growth hormone studied for fat metabolism without the growth-signaling effects of full HGH.